Skip to content
PatentBrief
Get alertsTop ↑

Targeting Drugs with a Special Polysarcosine Polymer Chain

This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.

ActiveExpires 2044Owned by Mablink Bioscience SASInvented by Warren VIRICEL

Original patent title: “Ligand-drug-conjugate comprising a single molecular weight polysarcosine”

Plain-English explanation by SahiLast reviewed · November 3, 2026

This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight. Owned by Mablink Bioscience SAS with 21 claims, and it is expected to expire in 2044.

Coverage

What does this patent actually cover?

This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.

The gap

What does this patent NOT cover?

  • Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover LDCs where the polymer is not a 'homopolymer' (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1), meaning it would not cover conjugates made with copolymers or other polymer types.
  • Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 2).
  • Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 20250057964
StatusActive
FieldBiotech & Medicine
AssigneeMablink Bioscience SAS
InventorWarren VIRICEL
Filed2024
Expires2044
Claims21
Times cited0
LitigationNone on record
Value · $59K–$187KModest

What made this novel

The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.

The Patent Drawing

Representative patent drawing for Ligand-drug-conjugate comprising a single molecular weight polysarcosine (US 20250057964)
Representative figure · US 20250057964All figures on Google Patents →
Ligand-drug-conjugate comprisi…(Primary claim)pharmaceuticalbiotechmaterials

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Antibody-drug conjugates (ADCs) in cancer therapy

02

Targeted drug delivery systems for chemotherapy

03

Biologics with enhanced half-life or reduced immunogenicity

04

Polysarcosine-based drug carriers

Why it matters

The bigger picture

Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.

Filed

September 24, 2024

Market context

Who's building on this

Companies in this space

Mablink Bioscience SAS, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is actively developing next-generation antibody-drug conjugates using polysarcosine-based linkers. Other major pharmaceutical companies and biotech firms focused on targeted drug delivery, such as Seagen (now part of Pfizer), Genentech (Roche), and AstraZeneca, are also heavily invested in advancing LDC technology, continually seeking improved linker and polymer chemistries.

Market impact

This patent contributes to the rapidly evolving field of targeted drug delivery, particularly for cancer therapies. By proposing a more precise polymer component, it could enable the development of LDCs with improved therapeutic windows, meaning better efficacy with fewer side effects. This could lead to new drug candidates that are more stable and predictable, potentially expanding the market for highly potent, targeted medicines and offering new treatment options for patients.

Claim 1 — Plain English

What this patent covers

This patent describes a Ligand-Drug-Conjugate (LDC) compound designed to deliver a drug, typically a cytotoxic drug, to a specific target in the body. The LDC (formula XV) uses a 'single molecular weight homopolymer' (Claim 1), which is preferably polysarcosine (Claim 2). This special polymer is connected to the drug via an 'orthogonal connector' (L), ensuring the polymer is positioned distinctly from the drug and its linker (X-D). The drug (D) can be released from the LDC using an optional 'cleavable moiety' (X), which might be triggered by conditions in the body, like acidic environments in lysosomes (Claim 9). For example, a cancer-targeting antibody (the ligand, Claim 5) could be attached to this polysarcosine chain, which then carries a chemotherapy drug directly to tumor cells, releasing it only when it reaches the target.

The clever bit

The clever bit is using a 'single molecular weight homopolymer,' specifically polysarcosine, as the polymer component in a drug conjugate. This provides precise control over the polymer's size and properties, which can improve drug stability and reduce variability in how the drug behaves in the body.

What it does not cover

  • Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).
  • Does not cover LDCs where the polymer is not a 'homopolymer' (Claim 1), meaning it would not cover conjugates made with copolymers or other polymer types.
  • Does not cover LDCs that use polymers other than polysarcosine as the single molecular weight homopolymer (Claim 2).
  • Does not cover LDCs where the polymer is not in an 'orthogonal orientation' with respect to the drug and its linker (Claim 1).
  • Does not cover drug conjugates where the drug is not attached via an 'orthogonal connector' (L) as defined (Claim 1).

Patent timeline

Filing

Application submitted to the patent office

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Limited data

Citation count

0/40

No citations yet

Claim breadth

14/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

0/20

Older than 20 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$59K – $187K

Midpoint $117K · 17.8 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

21 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Cite this patent

VIRICEL, W. Targeting Drugs with a Special Polysarcosine Polymer Chain (U.S. Patent No. 20,250,057,964). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20250057964/ligand-drug-conjugate-comprising-a-single-molecular-weight-polysarcosine

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US20250057964"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:pharmaceutical patents →biotech patents →materials patents →

Common Questions

Frequently Asked Questions

What does Targeting Drugs with a Special Polysarcosine Polymer Chain cover?

This patent describes a new way to deliver drugs, especially for cancer, by attaching them to a specific type of polymer called polysarcosine that has a very precise, single molecular weight.

Who owns patent US 20250057964?

This patent is owned by Mablink Bioscience SAS.

When does this patent expire?

This patent is expected to expire on September 24, 2044, when the invention enters the public domain.

What problem does this patent solve?

Ligand-Drug-Conjugates are a crucial class of medicines, especially for treating cancer, because they can deliver potent drugs directly to diseased cells while sparing healthy ones. Using a 'single molecular weight' polysarcosine polymer, as claimed, could lead to more consistent drug products with predictable behavior in the body. This precision might reduce side effects and improve treatment effectiveness compared to conjugates made with polymers that have varying chain lengths. This approach aims to enhance the stability and targeting capabilities of these complex therapeutic molecules.

What does this patent NOT cover?

Does not cover Ligand-Drug-Conjugates that use homopolymers with a range of molecular weights, only those with a 'single molecular weight' (Claim 1).

Patent monitoring

Get notified when Mablink Bioscience SAS files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 3, 2026 · PatentBrief is not a law firm and this is not legal advice.